Proprotein Convertase Subtilisin Kexin Type 9 Promotes Intestinal Overproduction of Triglyceride-Rich Apolipoprotein B Lipoproteins Through Both Low-Density Lipoprotein Receptor–Dependent and –Independent Mechanisms | Zendy

Shirya Rashid | Zendy; Hagai Tavori | Zendy; Patrick Brown | Zendy; MacRae F. Linton | Zendy; Jane He | Zendy; Ilaria Giunzioni | Zendy; Sergio Fazio | Zendy

Open Access

Proprotein Convertase Subtilisin Kexin Type 9 Promotes Intestinal Overproduction of Triglyceride-Rich Apolipoprotein B Lipoproteins Through Both Low-Density Lipoprotein Receptor–Dependent and –Independent Mechanisms

Author(s) -

Shirya Rashid,

Hagai Tavori,

Patrick Brown,

MacRae F. Linton,

Jane He,

Ilaria Giunzioni,

Sergio Fazio

Publication year - 2014

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/circulationaha.113.006720

Subject(s) - kexin , proprotein convertase , pcsk9 , subtilisin , medicine , apolipoprotein b , overproduction , triglyceride , lipoprotein , endocrinology , apolipoprotein c2 , ldl receptor , very low density lipoprotein , biochemistry , cholesterol , biology , gene , enzyme

Proprotein convertase subtilisin kexin type 9 (PCSK9) promotes the degradation of the low-density lipoprotein (LDL) receptor (LDLR), and its deficiency in humans results in low plasma LDL cholesterol and protection against coronary heart disease. Recent evidence indicates that PCSK9 also modulates the metabolism of triglyceride-rich apolipoprotein B (apoB) lipoproteins, another important coronary heart disease risk factor. Here, we studied the effects of physiological levels of PCSK9 on intestinal triglyceride-rich apoB lipoprotein production and elucidated for the first time the cellular and molecular mechanisms involved.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research